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ABSTRACT
The human intestinal commensal microbiota and associated metabolic products have long been
regarded as contributors to host health. As the identity and activities of the various members of
this community have become clearer, newly identified health-associated bacteria, such as
Faecalibacterium prausnitzii, Akkermansia muciniphila, Ruminococcus bromii and Roseburia species,
have emerged. Notably, the abundance of many of these bacteria is inversely correlated to several
disease states. While technological and regulatory hurdles may limit the use of strains from these
taxa as probiotics, it should be possible to utilize prebiotics and other dietary components to
selectively enhance their growth in situ. Dietary components of potential relevance include well-
established prebiotics, such as galacto-oligosaccharides, fructo-oligosaccharides and inulin, while
other putative prebiotics, such as other oligosaccharides, polyphenols, resistant starch, algae and
seaweed as well as host gut metabolites such as lactate and acetate, may also be applied with the
aim of selectively and/or differentially affecting the beneficial bacterial community within the
gastrointestinal environment. The present review provides an overview of the dietary components
that could be applied in this manner.
ARTICLE HISTORY
Received 14 January 2019
Revised 12 April 2019
Accepted 26 April 2019
KEYWORDS
Prebiotics; beneficial
microbes; health-promoting
gut bacteria; microbiota
Introduction
The human gut is estimated to contain approxi-
mately 1014 bacteria comprising more than 1000
species.1,2 Intestinal commensal bacteria, as well as
their metabolic products, have long been recog-
nized as important contributors to host health,
including nutrition/energy homeostasis, pathogen
resistance, the regulation of intestinal epithelial
proliferation and a variety of other factors.3 The
corollary is that negative impacts on microbiota
composition and functionality can contribute to
illness.4,5 Importantly, the gut microbiota can be
modulated in a beneficial way, including through
the selective manipulation of particular species of
interest to maintain, restore or improve host health.
One approach to positively modulate the gut
microbiota is through the administration of growth
enhancing substrates that can be utilized selectively
by health promoting bacteria, to encourage their
growth and the production of associated desirable
metabolites. The rationale of selectively enhancing
beneficial microbes in the gut lead to the concept of
prebiotics, initially coined in 1995 by Roberfroid and
Gibson6 and described in greater detail below.
Among the best characterized prebiotics are galacto-
oligosaccharides (GOS) and inulin and its oligomer,
fructo-oligosaccharides (FOS), as evidenced by
numerous studies.7–9 The vast majority of studies
relating to these and other prebiotics have focused
on elucidating their effects on Bifidobacterium and
Lactobacillus as strains from these genera have been
known for some time to confer a health benefit to the
host.10 As our knowledge of the gastrointestinal
microbiota expands, emphasis has now also been
placed on the application of other bacteria present
with possible health promoting effects and, in paral-
lel, on the identification of prebiotics (targeted) and
other dietary substrates (potentially less targeted)
with the potential to stimulate the growth of these
beneficial targets in the gut.
Newly identified health-associated microbes
Advances made in metagenomics and the applica-
tion of emerging ‘multiomics’ technologies, in
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combination with cultivation techniques, have iden-
tified several putatively beneficial species of gut bac-
teria (Table 1). These microbes, including
Faecalibacterium prausnitzii, Ruminococcus bromii
and Akkermansia muciniphila, can be present in
significant numbers in a healthy human gut.
A single species such as F. prausnitzii may comprise
more than 5% of the total intestinal community,30
while there are also instances where up to 8% of the
composition has been assigned to the phylum
Verrucomicrobia,31 i.e., corresponding to
A. muciniphila at the species level.
Some of these newly identified health-promoting
bacteria are associated with various benefits to their
respective hosts. One example of such an apparent
relationship is the observation that the abundance
of F. prausnitzii is inversely correlated with inci-
dence of inflammatory bowel disease (IBD), in par-
ticular Crohn’s disease.19,23,32 As a result,
F. prausnitzii has been investigated with respect to
its potential to alleviate inflammation.32 Another
intriguing host-microbe interaction relates to that
between A. muciniphila and obesity. Accumulating
evidence has shown that the abundance of
A. muciniphila is inversely proportional to body
weight and type-1 diabetes.27,33 A. muciniphila is
specialized as it colonizes the mucus lining and can
use mucin as a sole carbon and nitrogen source,
releasing growth substrates for other beneficial
bacteria.34,35 Interestingly, in a recent study,
Roseburia hominis and Roseburia intestinalis have
also been found to utilize mucin as energy source
indicating that mucin degradation is more wide-
spread than was previously appreciated.36 Mucin
is a major component of intestinal mucus layer.
The ability to utilize mucin offers an ecological
benefit to these bacteria over those that are depen-
dent on dietary nutrients, providing a source of
host-derived nutrients while the geographical loca-
tion provides a means of interacting with the
immune system.37 Notably, Christensenella minuta
and Oscillospira spp. have also been linked with
a lean phenotype and may be useful targets when
combating obesity.11,24,28 The establishment of
Table 1. Overview of some representative newly identified health-promoting bacteria and the associated benefits.
Family Bacteria Beneficial Impact Reference(s)
Christensenellaceae Christensenella
minuta
SCFA producer and possible link with a lean phenotype. J.K Goodrich et al., 201411
Eubacteriaceae Eubacterium
eligens
SCFA producer and pectin utilizer. M. Lopez-Siles et al., 201212
Eubacteriaceae Eubacterium
hallii
Produces pseudovitamin B12 which can help ↑ SCFA
production by surrounding bacteria e.g. A. muciniphila,
lactate utilizer, butyrate producer
C. Belzer et al., 2017,13 S. Duncan et al.,
200414
Eubacteriaceae Eubacterium
rectale
Acetate consumer, butyrate producer. Can be involved in
cross-feeding interactions with other beneficial bacteria
e.g. Bifidobacterium longum.
A. Rivière et al., 2015,15 P. Louis et al.,
2010,16 P. Louis & H.J. Flint 200917
Lachnospiraceae Anaerostipes
caccae &
Anaerostipes
hadrus
Butyrate producers, lactate and acetate utilizers. S. Duncan et al., 2004,14 E. Allen-Vercoe
et al., 201218
Lachnospiraceae Coprococcus spp. Butyrate and acetate producers closely related to
Ruminococcus.
P. Louis & H.J. Flint, 200917
Lachnospiraceae Roseburia spp. Butyrate and propionate producers. Decreased levels seen
in those with ulcerative colitis.
K. Machiels et al., 2014,19 N. Reichardt et al.,
2014,20 S. Duncan et al., 200221
Ruminococcaceae Faecalibacterium
prausnitzii
Decreased levels observed in Crohn’s disease and
minulcerative colitis indicating anti-inflammatory
properties. One of the main butyrate producers within the
gut.
M. Lopez-Siles et al., 2012,12 A. Heinken
et al., 2014,22 S. Miquel et al., 2013,23
K. Machiels et al., 201419
Ruminococcaceae Oscillospira sp. Enriched in those with a lean phenotype in comparison to
obese subjects, decreased levels observed in those with
inflammatory diseases.
T. Konikoff & U. Gophna, 2016,24 J.K
Goodrich et al., 201411
Ruminococcaceae Ruminococcus
bromii
Keystone species for degrading resistant starch enabling
other bacteria to utilize the breakdown products.
X. Ze et al., 2012,25 A. Venkataraman et al.,
201626
Verrucomicrobiaceae Akkermansia
muciniphila
Mucin-degrading bacterium inversely associated with
obesity and other metabolic diseases. Liberates
oligosaccharides from mucin making them available to
other bacteria. Produces acetate and propionate which
some butyrate-producers can utilize.
PD. Cani & WM. de Vos, 2017,27 A. Everard
et al., 2013,28 C. Belzer et al., 2017,13
M. Schneeberger et al., 201529
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potential relationships such as these support the
continued efforts in identifying approaches to
encourage the growth of target microbes in the gut.
The breakdown and metabolism of complex
carbohydrates, particularly non-digestive carbohy-
drates, by gut bacteria, hugely benefits primary
degraders as well as the community which lack
the ability to use the parent components.
R. bromii has been suggested to be a key species
with respect to the breakdown of resistant starch,
with the resultant products being utilized as sub-
strates for syntrophic growth by other beneficial
microbes in the gut.25
While in some instances the benefits attributed
to specific gut microbes are thought to be direct, in
other cases they can be indirect, such as via their
metabolites. This can include the ability to utilize
fibers and complex carbohydrates to produce short
chain fatty acids (SCFAs),23,25,27 the most abun-
dant of which are acetate, propionate and butyrate.
SCFAs have numerous benefits including; lower-
ing the luminal pH, contributing to increased cal-
cium and magnesium absorption, helping to
reduce potential pathogenic bacteria, serving as
an energy source for epithelial cells and also invol-
vement in immune modulation. Butyrate, as men-
tioned previously, is produced mainly by
components of the major phylum, Firmicutes,
such as Clostridium clusters XIVa and IV,38 and
is particularly important as it is utilized as an
energy source for colonocytes and has a proposed
role in protection against diseases such as colon
cancer and colitis.39–42 It is therefore important
that these health-promoting bacteria are present
in sufficient numbers and are maintained within
the gut.
Other species that are abundant in a healthy gut,
including Lachnospiraceae such as Anaerostipes cac-
cae, Anaerostipes hadrus, Roseburia spp., Coprococcus
catus, and Eubacteriaceae such as Eubacterium rec-
tale and Eubacterium hallii, are acetate consumers
and produce butyrate via butyryl-CoA:acetate CoA-
transferase,43 which will be discussed in more detail
later. There are a number of other examples of
substrate cross-feeding that can have a substantial
impact on the survival of certain bacteria and pro-
duction of useful metabolites in the gut.44 For
instance, lactate is readily available in the gut as
a result of the activity of lactic acid bacteria and
can be utilized by Anaerostipes sp. and Eubacterium
sp. to produce SCFAs.45 Similarly, C. catus and the
ruminal bacterium Megasphaera elsdenii can convert
lactate to propionate via the acrylate pathway.20 The
metabolic diversity and dependency of these health
associated microbes is complex and, while our
understanding of the pathways involved in carbohy-
drate fermentation and cross-feeding are improving
(Figure 1), there is likely to be still much to learn.
Prebiotic criteria and considerations
A large number of studies have been conducted
to investigate a range of prebiotics and the
effects that they have on the gut microbiota.
With growing interest and knowledge, the defi-
nition of prebiotics has evolved and in
December 2016, the International Scientific
Association for Probiotics and Prebiotics
(ISAPP) proposed that the definition be revised
to ‘a substrate that is selectively utilized by host
microorganisms conferring a health benefit’.46
This definition expands the concept to include
non-carbohydrate substances. It also was sug-
gested that the revised definition does not limit
the selective stimulation of beneficial microor-
ganisms to the gut if in the future prebiotic
targets are beyond this environment. Currently,
in order to be classified as a dietary prebiotic,
three broad criteria need to be fulfilled. These
include (i) resistance to gastric acid and hydro-
lysis by mammalian enzymes and gastrointest-
inal absorption; (ii) ability to be utilized by the
intestinal microbiota; and (iii) selectively stimu-
late the growth and/or the activity of intestinal
bacteria associated with health-promoting
effects.47
A major prerequisite to the success of
a particular prebiotic is that the target bacteria
must be present or present at a specific threshold.
If levels are below a certain threshold, due to
factors such as ageing or antibiotic usage, then
the prebiotic may not be effective in increasing
the numbers of these desirable bacteria to the
necessary level in order to confer the anticipated
health benefits.26 Thus, having an understanding
of such factors in target populations can enhance
the likelihood of beneficial prebiotic-related out-
comes. However, there are a number of other
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factors to consider. While prebiotics, and other
beneficial food bioactives, can enable the growth
of targeted health-promoting bacteria, more
detailed microbiome analysis has highlighted that
these substrates are not always as specific as once
thought.46–48 It is also necessary to consider that
the benefits of prebiotics can sometimes be sec-
ondary, e.g., production by health promoting bac-
teria of metabolic products that can inhibit the
growth of enteric pathogens and/or attenuate
their virulence.49 One can determine prebiotic
impacts/specificity through the use of ex vivo fer-
mentation studies, with fecal samples or mock gut
microbial communities, or through in vivo studies.
However, even then, care should be taken when
interpreting outcomes as, due to inter-individual
differences, the same effect may not be observed in
all cases. It is also important to consider that some
populations, when present at sufficiently high
levels, may produce gases from prebiotic substrates
that can result in bloating and abdominal
discomfort.50,51 Additionally, some prebiotics
such as inulin-derived oligosaccharides can have
mildly laxative effects.52 All of these considerations
highlight the importance of understanding the
interactions between prebiotics (as well as other
dietary components), target microbes and the
metabolites generated in order to determine ulti-
mate resultant impacts on the host.
Targeting newly identified health-associated
microbes through well-established prebiotics
There are a few extensively studied prebiotics,
including FOS, GOS and inulin, which have been
examined in detail using in vitro assays and in vivo
animal models and human studies. These investi-
gations have in particular highlighted the growth-
promoting impact of prebiotics on members of the
genera Bifidobacterium and Lactobacillus,6,9,46,53 as
a consequence of the health-associated status of
many strains from these taxa. However, there are
Figure 1. Schematic representation of selected gut bacteria involved in carbohydrate fermentation and cross-feeding interactions
resulting in the production of major microbial metabolites.
Pathways leading to the production of the three main SCFAs, acetate, butyrate and propionate, are depicted here. Acetate can be
produced from acetyl-CoA or by acetogens using H2 and CO2 or formate. It can also be used for the formation of butyrate. Butyrate can be
formed in two ways; either through the formation of butyryl-P or more commonly through the use of butyryl-CoA:acetate CoA-transferase
which many Firmicutes possess. The main route by which propionate is generated is via the succinate pathway. However, two other
pathways have also been found; i.e., the acrylate pathway which involves lactate and the propanediol pathway which utilizes deoxyhexose
sugars. DHAP, dihydroxyacetonephospate; PEP, phosphoenolpyruvate. Adapted from Louis et al., 2014.43
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many ways in which prebiotics can positively
impact the host (Figure 2). A direct benefit of
prebiotics is enhancing the growth of target micro-
organisms which in turn compete with harmful
species for energy sources and exclude them prov-
ing protection or through facilitating the produc-
tion of beneficial fermentation products, such as
SCFAs.
Clinical trials and human studies are pivotal
when assessing the benefits of newly identified
prebiotics. Of the many studied potential prebio-
tics, only a few substrates, including inulin, FOS
and GOS, have been validated through several
human studies and only those that looked at
a broader gut community, and thus are of greater
relevance to this review, are presented in Table 2.
These studies have highlighted that the extensively
examined prebiotics, for example inulin, can also
have a positive effect on the level of F. prausnitzii
and Anaerostipes sp. within the gut, which may
explain some of the butyrogenic effects that ensue
when inulin is consumed.53,56,57 Likewise, FOS and
GOS have also been demonstrated to enhance
F. prausnitzii levels.53,55,56 Of the few human stu-
dies assessing the impact of prebiotics on micro-
bial diversity in the colon, contradictory
observations with regards to SCFA levels have
been reported. A study by Liu et al.54 noted
a decrease in the levels of butyrate producers and
increase in the levels of Bifidobacterium after
administration of FOS and GOS in a healthy
population, which may be caused by high levels
of lactic acid being produced, therefore making the
environment inhospitable for butyrate producers.
It is also worth noting that this intervention was
conducted for a period of 14 days; longer inter-
vention studies are needed to better evaluate the
effects of prebiotic administration. Nevertheless,
these results prove intriguing and emphasize the
need for more human studies.
Targeting newly identified health-associated
microbes through emerging prebiotics
The prebiotic paradigm has been shifting in recent
years as a result of the identification of newly
recognized putatively beneficial members of the
gut microbiota to target for enrichment. These
studies have been facilitated through new develop-
ments in cultivation techniques and, in particular,
high-throughput sequencing, culture-independent
approaches. These approaches have been used to
assess the impact of specific fibers as well as poly-
phenols, other oligosaccharides and the less
explored marine derived foods including seaweed-
based products, which represents a relatively
untapped source of food bioactives, on the gut
microbiota of animals and humans.
Polyphenols
Polyphenols are naturally occurring secondary
metabolites of plants that consist of a wide cate-
gory of compounds and are classified primarily
based on structure.63 Plant-based foods and bev-
erages, including fruits, vegetables, coffee, tea and
wine, are rich sources of dietary polyphenols.
Consumption of plant foods is associated with
lower risk of chronic diseases including cancer,64
heart diseases,65 type 2 diabetes66 and other
inflammatory diseases. A large number of these
biological effects are attributed to phytochemical
components of plant foods.67,68 Moreover, it has
been suggested that many of the beneficial impacts
of these secondary metabolites on overall health is
mediated through the manipulation of gut bacteria
Figure 2. An overview of some beneficial impacts of prebiotic
supplementation on the gut microbiota.
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Table 2. Human studies conducted in relation to prebiotics and newly identified health-promoting bacteria.
Prebiotic
Administered Study Design Cohort Delivery Effect on Microbiota Reference
Extensively studied prebiotics
FOS vs. GOS A randomized,
double-blind,
cross-over study
35 healthy
participants (10
males, 25
females)
16 g/d for 14 d FOS:
↑ Bifidobacterium; and ↓ in
Phascolarctobacterium,
Enterobacter, Turicibacter,
Coprococcus and Salmonella
GOS:
↑ in Bifidobacterium; ↓in
Ruminococcus,
Dehalobacterium, Synergistes &
Holdemania
Liu et al.,
201754
GOS A randomized,
double-blind,
parallel-group,
multisite placebo-
controlled study
62 lactose
intolerant
subjects
GOS or placebo was escalated in
5-d increments from 1.5 g to 15 g
once a day. Taken for 35 d
In response to GOS administration
↑ in Bifidobacterium,
Faecalibacterium & Lactobacillus
was observed. Subsequent dairy
consumption resulted in
↑ Roseburia levels
MA. Azcarte-
Peril et al.,
201755
Inulin-
oligofructose
Balanced cross-
over study
12 healthy adults
split into 2
groups (control
and prebiotic)
10 g prebiotic or control per day
over a 16-d period
↑ F. prausnitzii across all
volunteers & ↑ in different
Bifidobacterium species dependent
on individual as a result of
prebiotics
C. Ramirez-
Farias et al.,
200956
Inulin/
oligofructose
mix (50:50)
A double blind,
placebo
controlled,
intervention study
30 obese women 16 g prebiotic or control per day
for 3 months
Prebiotics led to ↑ in
bifidobacteria & F. prausnitzii while
↓ in Bacteroides intestinalis,
Propionibacterium & Bacteroides
vulgatus was observed
EM. Dewulf
et al., 201353
Inulin-type
fructans
A randomized,
double-blind,
placebo-
controlled, cross-
over trial
42 healthy adults 12 g chicory-derived Orafti inulin
or control per day for 4 weeks
Inulin consumption led to
↑ Bifidobacterium & Anaerostipes
abundances while Bilophila
numbers ↓
Vandeputte
et al., 201757
Potential prebiotics
Red wine
polyphenols
A randomized,
crossover-
controlled
intervention study
10 obese subjects
with metabolic
syndrome (MetS)
and 10 healthy
controls
Initial wash-out followed by two
intervention periods where
participants drank red wine
(272 mL/d) or de-alcoholised red
wine (272 mL/d) separated with
a wash-out phase (15 d) in
between cross-over
In healthy individuals ↑ levels in
F. prausnitzii & Roseburia after red
wine and de-alcoholised red wine
consumption in comparison to
baseline levels. MetS patients also
had ↑ levels in these bacteria
while also in Blautia coccoides-
E. rectale group and Lactobacillus.
Also, differences in microbiota
between both groups were
significantly ↓ after interventions
I. Moreno-
Indias et al.,
201658
Red wine
polyphenols
A randomized,
crossover,
controlled,
intervention study
10 healthy males After a 15-d wash-out period, each
participant completed 3
consecutive 20-d periods in which
they drank de-alcoholised red
wine (272ml/d), red wine (272ml/
d), or gin (100ml/d)
Red wine polyphenols
↑ Enterococcus, Prevotella,
Bacteroides, Bifidobacterium,
Bacteroides uniformis, Eggerthella
lenta & Blautia coccoides –
Eubacterium rectale groups
M. I. Queipo-
Ortuño et al.,
201259
Cocoa
flavanols
A randomized,
double-blind,
crossover,
controlled
intervention study
22 healthy
volunteers
Subjects either consumed high
cocoa flavanol (HCF – 494 mg) or
low cocoa flavanol (LCF – 29 mg)
drink per day for 4 wks followed
by 4 wk washout period before
switching to alternate drink
HCF ↑ Bifidobacterium &
Lactobacilli levels while ↓ levels of
C. histolyticum group. Both HCF &
LCF led to slight ↑ in E. rectale-
C. coccoides group but no
significant differences between
the two
X. Tzounis
et al., 201160
XOS A double-blind,
randomized,
placebo-
controlled study
32 healthy
subjects
1.4 g XOS, 2.8 g XOS or placebo
taken daily
Both XOS doses ↑ bifidobacteria,
no change in lactobacilli, ↑ in
Faecalibacterium sp. &
Akkermansia sp. in those
supplemented with the higher
dose
S. Finegold
et al., 201461
(Continued )
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in the colon and their transformation therein by
the gut bacteria present.69 One such example is
cranberry extract, which is rich in polyphenols,
and has been shown to ameliorate diet-induced
obesity and several features of metabolic syndrome
(MetS) in mice, while increasing the abundance of
A. muciniphila.70 Cranberry administration has
also been shown to enhance mucus secretion,
which could possibly create favorable conditions
for A. muciniphila.71 Similarly, the administration
of Concord grape and California table grape
extracts, rich in a class of polyphenol called
proanthocyanidin, also increases the abundance
of Akkermansia.72,73 Other polyphenols present
in red wine, tea and cocoa flavonols have also
been investigated. Cocoa flavanols increase the
levels of lactobacilli and bifidobacteria in addition
to enhancing levels of the Clostridium coccoides-
Eubacterium rectale group subtly.74 From a red
wine perspective, intake of 272 mL per day over
a 30-d period altered the composition of the gut
microbiota in patients with MetS and resulted in
increased levels of Bifidobacterium, Lactobacillus,
F. prausnitzii and Roseburia sp.58 The study also
suggests that the increase in F. prausnitzii levels
was associated with the decrease of blood glucose
levels in MetS patients possibly due to the produc-
tion of SCFAs interacting with gut hormones
which in turn may have an impact on carbohy-
drate metabolism.58 In the same study, beneficial
modulatory impacts in healthy volunteers were
attributed to red wine polyphenols as levels of
Blautia coccoides – Eubacterium rectale group, bifi-
dobacteria, Bacteroides uniformis and Eggerthella
lenta were enhanced. Consequently, there was
a significant decrease in the levels of the poten-
tially harmful Clostridium histolyticum group,
which encompasses some pathogens such as
Clostridium perfringens. Although the exact
mechanisms involved are not fully understood,
these in vitro and human studies form the basis
of utilizing certain polyphenols, alone or in com-
bination, to alter the composition of the gut
microbiota.
Oligosaccharides
In addition to the well-studied oligosaccharides, FOS
and GOS, more recently there have been many stu-
dies focusing on the prebiotic effect of other oligo-
saccharides, such as xylo-oligosaccharides (XOS)
and arabinoxylan (AX), pectin-oligosaccharides
(POS), isomatlooligosaccharides (IMO), soybean oli-
gosaccharides and human milk oligosaccharides
(HMOs).
XOS is the product of the hydrolysis of xylan and
can act as a substrate for gut bacteria, resulting in
the production of SCFAs,75 with associated health
benefits. The selectivity of XOS was noted in a study
where 6 out of 11 Firmicutes examined, including
R. intestinalis, R. faecis, E. rectale and A. caccae,
were able to utilize this substrate, along with some
Bifidobacterium sp. such as B. adolescentis.76
A number of studies have highlighted that XOS
Table 2. (Continued).
Prebiotic
Administered Study Design Cohort Delivery Effect on Microbiota Reference
Resistant
starch (RS)
A randomized,
crossover dietary
study
39 subjects with
reduced insulin
sensitivity
Participants either consumed
a high (HC) or low carbohydrate
(LC) diet followed by a baseline
diet. Then the HC subjects
consumed either a high RS (HRS –
66 g/d) or low RS (LRS – 4 g/d).
Subjects which consumed LC diet
consumed either 48 g for HRS or
3 g for LRS
HRS led to ↑ in the ratio of
Firmicutes to Bacteroidetes in
comparison to LRS. In particular
there were ↑ levels of
F. prausnitzii, Ruminococcus,
Roseburia, E. rectale &
A. muciniphila
TV. Maier et al.,
201762
Resistant
Starch (RS)
type 2
A balanced study 20 healthy young
adults (10 male &
10 female)
48 g of potato starch (24 g twice
per day) for 7 d after
a 3-d acclimatization period
Individuals with high or enhanced
levels of butyrate concentrations
showed ↑ in B. adolescentis or
R. bromii after RS consumption. In
5 individuals an ↑ in E. rectale was
observed. Huge inter-individual
variation was evident
Venkataraman
et al., 201626
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can have a bifidogenic effect. In one instance,
a human study evaluated the impact of XOS alone
and XOS in conjunction with inulin. XOS alone
increased fecal Bifidobacterium and butyrate, with
a decrease in acetate and p-cresol and the combina-
tion of substrates appeared to reduce the inflamma-
tory repercussions of a Western diet.77 XOS
supplementation was also determined to increase
Faecalibacterium sp. and Akkermansia sp. as well as
bifidobacteria but did not have a significant impact
on levels of lactobacilli.61 This study demonstrated
that XOS promoted intestinal health through mod-
ulation of the microbial community; although there
was no notable net increase in SCFA production
detected, due consideration must be taken when
examining dose effects.
Arabinoxylan (AX), a non-digestible carbohy-
drate often found in the cell walls of plants, can be
selectively fermented in the colon by fibrolytic gut
bacteria possessing AX-degrading enzymes.78 AX
can be hydrolyzed to arabinoxylan-oligosaccharides
(AXOS). Both AX and AXOS have demonstrated an
ability to increase desirable bacteria and butyrate
producers in the colon.79–81 Indeed, in one instance
when a high-fat (HF) diet was administered to mice,
the addition of AX subsequently increased levels of
bifidobacteria.80 AX also restored bacterial levels to
that of the initial control level before HF diet induced
obesity, in particular enhancing populations of the
Roseburia species and Bacteroides-Prevotella species
that were reduced upon HF feeding. These microbial
shifts as a result of AX supplementation highlight its
prebiotic potential.
Pectin and pectic oligosaccharides (POS) have
been identified as emerging prebiotics as evidenced
through their selective utilization by certain mem-
bers of the colonic microbiota such as E. eligens and
F. prausnitzii.12,82 The most frequent source of pec-
tin is from citrus fruits and apple pulp, but it is also
abundant in agricultural by-products such as sugar
beet pulp. POS can be obtained through depolymer-
ization of pectin and both pectin and POS escape
host digestion and reach the distal colon when
consumed.83 In an in vitro assay of F. prausnitzii
growth in the presence of different substrates, it
was ascertained that growth was enhanced with
apple pectin in most cases.12,84 Although pectin is
extensively fermented in the gut, pectin utilization
has not been reported for many of the bacterial
groups residing in the gut. It has been demonstrated
that one of the main fermentation products from
pectin utilization by F. prausnitzii was butyrate.
The ability of F. prausnitzii to compete for pectin
when cultured with B. thetaiotaomicron and
E. eligens was also noted.12 Growth on some uronic
acids such as galactouronic acid was also observed in
F. prausnitzii. This is important as galactouronic acid
is a major component of pectin and it is not reported
to be utilized by many other bacterial groups other
than Bacteroides sp.12 The impact of sugar beet pulp
and lemon peel wastes on gut microbial commu-
nities have also been assessed using in vitro fermen-
tation assays.85 Results suggested that POS of both
lemon peel and sugar beet possessed better prebiotic
potential than the corresponding pectin, and similar
or even better than FOS (which was used as
a control). Lemon peel waste oligosaccharides
(LPOS) in particular resulted in an increased level
of Faecalibacterium and Roseburia sp. as well as
lactobacilli. Both LP and LPOS increased the level
of E. rectale, although larger effects were observed
with pectin. Ultimately, the study indicated that POS
and pectin brought about a beneficial impact on the
microbial population, presenting an intriguing
opportunity for further investigation.
Isomaltooligosaccharides (IMO) are often consid-
ered potential prebiotics. Their impact on newly iden-
tified health beneficial microbes is limited and
necessitates further investigation. IMOs are naturally
found in foods such as honey as well as fermented
foods such as miso and soy. In addition, various
commercial preparations are made enzymatically by
processing an assortment of starches and are readily
available on themarket today. Commercially available
IMOs are composed of a mixture of α(1–6) and α
(1–4)-linked glucosyl oligosaccharides.86 One of the
glucose oligomers identified in IMOs is isomaltose,
which is a major constituent of honey thereby giving
IMOs a distinctive sweet honey taste. In a recent study
evaluating the impact of co-supplementation of cran-
berry extract with IMO in HF diet fed mice,
Roseburia, Faecalibacterium, and Eubacterium were
enhanced with an associated increase in butyrate.87
Unsurprisingly, HMOs have also been the focus
of much attention, with strong effects being
observed on Bifidobacterium levels in particular.88
Breast milk is the natural first nutritional source for
newborns and provides oligosaccharides that
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promote the growth of desirable Bifidobacterium
sp. in the infant gut. HMOs and other nutrients in
breast milk can act as substrates for bacteria in the
gut, thereby stimulating the growth of beneficial
bacteria located here. Two compounds in HMOs
are 2ʹ-O-fucosyllactose and lacto-N-neotetraose,
which was the subject of one human study evaluat-
ing their putative prebiotic effect on the human gut
microbiota in 100 healthy, adult volunteers.89 This
HMO supplementation was shown to modify the
gut microbiota with a resulting increase in the rela-
tive abundance of Actinobacteria and, in particular
Bifidobacterium, while reducing the relative abun-
dance of Firmicutes and Proteobacteria. While
there are much data available relating the impact
of HMOs on the infant gut, and of Bifidobacterium
strains found therein,90 their full effect on the over-
all infant gut microbial population, and resulting
adult microbiota, is the subject of many on-going
investigations.
Other oligosaccharides, including those from
soybean and mannan, have putative prebiotic
effects. Soybean oligosaccharides seem to have
a positive influence on Bifidobacterium levels and
lactate production.91 Soybean forms a substantial
part of diets in Asia and is now more frequently
seen in Western diets, and benefits are attributed
partly to fiber and the oligosaccharides present.
Mannan-oligosaccharides (MOS) are commonly
used as additives in animal feeds. MOS are not
absorbed by the animal so can reach the gut
microbiota where they are utilized beneficial bac-
teria such as bifidobacteria and lactobacilli which
can out-compete potential pathogenic bacteria.
The effect on animal intestinal bacteria and
mechanisms involved is just beginning to be
evaluated.92 Although their effect on human gut
intestinal inhabitants has yet to be assessed, there
may be considerable merit in doing so.
Combinatorial benefits of various oligosaccharides
are also beginning to be assessed, which may lead
to the identification of optimal levels and combi-
nations of prebiotics for the promotion of health-
associated bacteria in the gut.93
Resistant starch
Resistant starch (RS) is a form of starch that can-
not be degraded in the small intestine and, thus,
subsequently reaches the large intestine where it is
fermented by the colonic bacteria. There are four
types of RS (type 1–4), each with different proper-
ties that contribute to resisting digestion. RS1 is
physically inaccessible due to its compact struc-
ture, RS2 has a granular structure, which prevents
digestive enzymes from hydrolyzing it, RS3 are
retrograded starches and RS4 is modified with
chemicals to enhance resistance. RS2 has been
the focus of many investigations, both ex vivo
and in humans. Interestingly, in a co-culture
experiment, R. bromii demonstrated a unique abil-
ity to stimulate RS degradation by other bacteria.25
When cultured with E. rectale, B. thetaiotaomicron
and B. adolescemtis on YCFA (yeast extract-
casitone-fatty acid) medium, a semi-defined med-
ium, utilization of RS was enhanced in comparison
to combinations without R. bromii. This is intri-
guing as it was determined that YCFA medium did
not support the growth of R. bromii very well. This
indicates that R. bromii has a superior ability to
ferment RS and even possibly produce metabolites
that are available for cross-feeding interactions
with co-inhabitants. Many studies have particu-
larly emphasized the importance of R. bromii as
a keystone species with regard to degrading RS
within the human gut.25,26,94 The R. bromii popu-
lation substantially increased in fecal samples col-
lected from those consuming a high RS diet.25
Venkataraman et al.26 demonstrated that RS2,
when used to supplement the normal diet of healthy
volunteers, increased fecal butyrate concentrations
albeit with considerable inter-individual differ-
ences. This high amylose starch enhanced SCFA
production, although those with low initial levels
of SCFAs did not increase substantially, indicating
that possibly the baseline level of required bacteria
was too low for the full benefits of supplementation
to be achieved. In those where an effect was evident,
there was a substantial increase in RS-degrading
bacteria such as B. adolescentis and R. bromii with
some individuals displaying an additional enhanced
level of E. rectale.
Similarly, in a study evaluating the effect of RS2
on subjects with insulin resistance using a multi-
omics approach, a high-RS diet resulted in an
increased Firmicutes to Bacteroidetes ratio, with
a particular enhancement of F. prausnitzii,
R. bromii and Roseburia species.62 The Firmicutes
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to Bacteroidetes ratio has been used, albeit some-
what controversially, as amarker of gut homeostasis
with increased proportions Bacteroidetes being pro-
posed to reflect a beneficial modulation of gut
microbiota. There is evidence to suggest that differ-
ent types of RS may lead to distinct compositional
modulations. In a study examining the effect of RS2
or RS4 on the composition of the fecal microbiota in
10 human subjects, in line with the aforementioned
studies RS2 enriched B. adolescentis, R. bromii and
E. rectale.95 On the other hand, RS4 increased the
levels of Parabacteroides distasonis and R. bromii
and decreased the levels of E. rectale. Both
R. bromii and E. rectale were also enriched in fecal
samples of obese human subjects during consump-
tion of RS3 indicating some similarity to RS2.96 This
highlights the importance of the chemical structure
of RS in dictating its impact on the colonic bacteria.
A recent dietary intervention study looked at the
impact of two different RS, one from potatoes and
the other from maize, as well as inulin on the gut
microbiota of healthy volunteers.97 Both types of RS
were RS2 although the resulting changes in the gut
microbiota differed with the RS frompotatoes yield-
ing a greater increase in SCFA production than
either RS from maize or inulin. Again, the presence
of R. bromii was significant. It was noted that if
either R. bromii or Clostridium charatabidum were
present after consuming RS it was more likely for
butyrate to be produced, especially when the micro-
bial population included the butyrate-producer
E. rectale. This indicates that there may be primary
degraders of RS such as R. bromii and the break-
down products may subsequently be utilized by
certain butyrate-producers. Bifidobacterium was
also enhanced in most of the gut microbiotas after
consuming any of the three fermentable fibers. The
resulting effects of RS degradation on the microbial
population has yet to be fully explored, however, it is
evident that R. bromii has an integral role in initiat-
ing the breakdown of this resistant but fermentable
starch. This selectivemetabolism is the driving force
behind the ever-increasing interest in the use of RS
as a prebiotic ingredient in functional foods.98
Indeed, several commercialized products contain-
ing RS are already available on the market and there
has been a continuing effort to incorporate the RS as
a functional food component.
Algae and seaweed
The marine environment is often considered a vast,
untapped reservoir with regards to the microorgan-
isms and compounds present, the metabolites pro-
duced and interactions that occur in this ecosystem.
New bioactives and potential prebiotic substrates are
being harnessed from this rich environment.
Seaweeds, also known as marine macroalgae, are
rich in polysaccharides and bioactive compounds,
which could be applied to improve human and animal
health.99,100 Seaweeds can be subdivided into three
categories based on their pigmentation; Rhodophyta
(red seaweed), Chlorophyta (green seaweed) and
Phaeophyta (brown seaweed).99 Differences in com-
position and structure of the polysaccharides present
in these seaweeds are also evident. Brown seaweed is
of particular interest as it possesses polysaccharides
such as fucoidan, laminarin and alginate.101
Fucoidans comprise a class of fucose-rich sulfated
polysaccharides often located in the cell walls of
brown macroalgae. It is suggested that fucoidans
with differing structures may impact the gut in
a variety of ways. For example, a study carried out
by Shang et al.,102 established that fucoidans isolated
from Ascophyllum nodosum (FuA) and Laminaria
japonica (FuL) had positive but slightly differing
effects on the murine gut microbiota due to their
structural differences. FuA has a type I back-bone
structure whereas FuL has a type II structure. FuL
markedly increased the levels of Ruminococcaceae
while FuA enhanced Lactobacillus, Anaeroplasma
and Thalassospira. In a follow-up study on HF diet-
fed mice, these fucoidans improved MetS induced by
a HF diet.103 Dietary supplementation with fucoidan
decreased body weight in HF diet-fed mice and also
improved glucose intolerance and insulin resistance.
Both fucoidans separately ameliorated intestinal dys-
biosis caused by HF diet and significantly increased
Akkermansia abundance. An evolving body of evi-
dence has linked A. muciniphila with a lean pheno-
type and often levels are lower in those with obesity
and its related metabolic alterations. Additionally,
SCFA producers such as Blautia and Alloprevotella
were increased. This contributes to the improvement
of the health status of the gut microbial community.
Remarkably there did not seem to be any major
differences between FuL and FuA in this instance as
both influenced the gut bacterial community
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correspondingly. Thus, ingredients from marine
resources, particularly fucoidan, have potential as
mediators of gut microbes.
Other components influencing growth
Gut metabolites as modulators
Apart from dietary and environmental factors, the
host-derived as well as microbial-derived metabo-
lites in the gut can act as modulators of the gut
ecosystem. Lactate is one of the many studied
metabolites. Interest in lactate as a substrate to
impact on the gut microbiota has increased in
recent years due to the fact that some lactate-
utilizing bacteria have the ability to produce
butyrate.14 Notably, E. hallii and A. caccae have
demonstrated an ability to use both D- and
L-lactate.14 Evidence of lactate being utilized in
cross-feeding studies is particularly intriguing as
it may explain the butyrogenic effect of certain
dietary bioactives, including resistant starch.14,104
Indeed, Bifidobacterium and Bacteroides who are
known degraders of RS do not produce butyrate. It
is hypothesized that these active starch degraders
may produce lactate initially and that, subse-
quently, lactate utilizers such as E. hallii and
A. caccae may produce butyrate using lactate as
a substrate.14 The synergistic effect of this cross-
feeding mechanism highlights the intricate and
elaborate relationships of co-inhabitants within
the gut. Interestingly, synbiotic administration of
A. caccae and GOS improved beneficial organic
acid production in comparison with GOS
alone.105 Also, in a separate study, Roseburia sp.
strain A2-183 was unable to consume lactate or
grow on potato starch or FOS in pure culture, but
when co-cultured with B. adolescentis L2–32 in the
presence of starch or FOS, the bacterium produced
butyrate.104
As noted earlier, acetate is the most abundant
SCFA in the colon and while it is normally an end-
product of anaerobic fermentation, it can also be
utilized by some butyrate-producing species within
the gut.106 For example, F. prausnitzii, one of the
most abundant bacteria in the colon, is also
a prominent acetate-consumer14 and grows poorly
on media deficient in acetate.107 Along with
F. prausnitzii, R. intestinalis and E. rectale are also
known acetate consumers.106,108 Although they are
unable to use acetate as a sole source of energy, they
do show net utilization of acetate possibly to produce
butyrate via acetyl-CoA formation. Strains of
F. prausnitzii and Roseburia sp. possess butyryl-
CoA:acetate-CoA transferase which is involved in
catalyzing butyryl-CoA to butyrate.106 This reaction
may also be carried out by butyrate kinase instead of
the transferase.109 Other members of the intestinal
microbiota may also play a role in making acetate
available for utilization by other microbes present in
the gut.A. muciniphila has the ability to degrade and
utilize host mucus and consequently can produce
1,2-propanediol, acetate and propionate, thereby sti-
mulating the nearby butyrate producers as a result of
this specialized activity within this niche
environment.13 Barcenilla et al., working with
human fecal samples, demonstrated that 95% of
strains isolated that were net acetate utilizers were
butyrate producers.108 Half of butyrate-producing
isolates examined in this study, however, exhibited
net acetate consumption. Not all acetate, of course, is
re-directed for butyrate synthesis. However, there
appears to be a strong link between acetate con-
sumption and butyrate production by colonic bac-
teria. Further exploration to establish to what degree
acetate is required for colonic butyrate production is
necessary in developing our understanding of this
relationship.
N-acetylglucosamine (GlcNAc) and
N-acetylgalactosamine (GalNAc) are host-derived
monosaccharide derivatives of glucose and galactose,
respectively, and are found abundantly in the mucus
lining of the gut.35 As noted, A. muciniphila is an
intestinal bacterium that resides in this ecological
niche.29,110 This beneficial bacterium is adept at
colonizing the mucus lining and has the ability to
utilize a number of sugars including GlcNAc and
GalNAc, although optimal growth in vitro is
achieved with media containing mucin.35 Other
components of mucin may further enhance its
growth.
The more recent generation of culture-
independent, sequence-based understanding of
gut communities facilitates the use of computa-
tional modelling to elucidate metabolic functions
possessed by a single species22,111 or microbial gut
communities,112 as well as predicting possible
growth substrates based on the pathways present.
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Based on whole genome sequences, models have
been developed to predict the metabolic capabil-
ities of F. prausnitzii22 and A. muciniphila111,113 in
silico. The ability of microbes to utilize a variety of
carbohydrates, including the host-derived sugar
GlcNAc, and amino acids or other growth promo-
ters can be confirmed with cultivation experi-
ments. In evaluating the predicted conditions,
GlcNAc was found to enhance the growth of
F. prausnitzii better than glucose.22 This ability
was also observed in several tested strains of
F. prausnitzii suggesting that multiple strains can
grow well on GlcNAc, highlighting its ability to
utilize both diet- and host-derived substrates.12
Although GlcNAc is not commonly found in
foods, it is found in mushrooms as GlcNAc is
a monomer of chitin114 and GlcNAc supplements
are also available on the market.
Minerals
Minerals, such as iron, magnesium, sodium and
calcium, are essential elements for living organisms,
including most bacteria, and play pivotal roles in
many biological processes. They are present abun-
dantly in many food sources and, when these foods
are ingested; microbes in the gut have access to these
minerals. Although a little is known about the reg-
ulation of mineral absorption mediated by gut bac-
teria and their impact on the gut microbiota,
information on the importance of major dietary
minerals on health is available. Of these, iron has
sparked the interest of many researchers over the last
number of years, with a focus on the impact on
malnourished children. Iron deficiency is very pre-
valent among African children with the WHO esti-
mating 62.3% of preschool children are anemic.115
Iron-containing micronutrient powders (MNPs) are
added to foods in a bid to reduce iron deficiency and
prevent anemia in children but the impact of iron
supplementation on gut microbiota composition
and functions has yielded conflicting results.116–119
These differences might be partly due to age-related
differences in various cohorts, diverse geographical
settings, the variety of iron compounds involved and
the doses administered in the different studies,
which are summarized below.
The impact iron exerts on the production of
bacterial metabolites, in particular butyrate, has
also been the focus of some investigations.
Butyrate seems to be strongly affected in response
to iron. In one in vitro colonic fermentation
model, moderately low levels of iron increased
butyrate production whereas very low levels
impaired its production.119 The same study
found that under high iron conditions, an
increase in abundance of propionate-producing
Bacteroidaceae and a decrease in butyrate-
producing Lachnospiraceae were reflected based
on the metabolites produced. Butyrate levels pro-
duced by R. intestinalis in batch culture were
negatively affected by low iron levels while lactate
and formate were enhanced. The results were
reversed with high iron levels suggesting that
levels of a single mineral can have a big impact
on gut microbiota. However, some recent data
has indicated that iron supplementation has
adverse effects on the gut microbiota.116,117,120
Notably iron supplementation resulted in
decreased levels of desirable bacterial groups
such as Bifidobacteriaceae and Lactobacillus and
increased levels of Enterobacteriaceae. The pro-
duction of siderophores in many pathogenic bac-
teria may have been responsible for the latter
phenomenon.116 One intriguing study by
Paganini et al.120 involving three groups of
Kenyan infants demonstrated that the addition
of GOS with a MNP containing iron (FeGOS
group) mitigated the adverse effects observed in
comparison to children that were administered
the MNP and iron without the prebiotic (Fe
group). The FeGOS group exhibited a similar
gut microbiota composition to the control group
(MNP without iron or GOS) but had lower levels
of virulence and toxin genes (VTGs) and
increased production of SCFAs. On the other
hand, a shift in microbiota composition to
a more adult-like community was observed in
the Fe group. Thus, the prebiotic seemed to sta-
bilize the gut microbial community by limiting
the negative effects induced by the addition of
iron. Further, the addition of GOS did not seem
to affect the bioavailability of iron. The MNP
used in this study was fortified with 5 g of iron,
i.e., much lower than the average amount of
12.5 g used in standard MNP supplements in
earlier studies.121 The lower dose maintained effi-
cacy in that the iron was of high bioavailability
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and reduced anemia so therefore may be more
suitable than the current high dose levels which
are between 10 and 12.5 mg of fortified iron
according to the WHO.122 As noted, the varying
doses and iron compounds investigated through-
out the literature highlight a need for standardi-
zation in supplementation regimes. However,
achieving this across different cohorts is difficult
as many factors contribute to iron bioavailability
and differences in microbiota across different
populations makes it difficult to establish the
complete impact of iron.
The effect of other minerals on the gut microbiota,
in particular bacteria recently identified as beneficial,
is currently not well understood.While there are some
insights to suggest that other minerals, such as zinc,
can have an impact,123,124 little is currently known.
Synbiotics
Synbiotics have also attracted significant attention in
recent years. Synbiotics are combinations of
a probiotic and an appropriate prebiotic designed to
enhance specifically the growth and survival of the
probiotic or other desirable bacteria within the gastro-
intestinal environment, enabling beneficial effects to
be induced more effectively.125 This provides a very
practical method of overcoming the difficulties that
a probiotic may endure when initially introduced into
the gut environment. Challenges in designing
a synbiotic include selecting the right combination of
pro- and prebiotic and ensuring sufficient quantities
of each. As bifidobacteria and lactobacilli are well-
characterized members of the human intestinal con-
sortiumand the benefits of specific strainswith respect
to humanhealth have been established,microbes from
these genera are most frequently included in synbio-
tics. FOS, GOS, inulin and lactulose are common
choices for synbiotic formulations. Some newly iden-
tified health-promoting bacteria have been the focus
of investigations to assess the consequence of combin-
ing their use with some well-established prebiotics.
For example, a synbiotic administration of A. caccae
L2 with GOS to rats enhanced intestinal organic acid
production more effectively than just GOS alone.105 It
was hypothesized that GOS increased levels of bifido-
bacteria, resulting in greater lactate production, which
in turn promoted A. caccae growth, therefore, facil-
itating the production of butyrate by A. caccae. This
demonstrates one way of utilizing the complex cross-
feeding mechanisms to selectively manipulate target
microbes.
Conclusion
The human gut harbors a diverse collection of
microbes whose interactions and functionality have
yet to be completely elucidated. However, it is already
clear that these microbes play an integral role in
human health and well-being. An increasing aware-
ness that various microbes that can influence human
health has been a catalyst for an ever-rising number of
investigations into benefits of gut microbiota manip-
ulation. Prebiotics, and other nutrients, targeted to
specific health-promoting bacteria are establishing
themselves as a significant means of improving host
health and disease. This has been evident in the con-
siderable body of work that has accumulated in the
last few years by demonstrating that species composi-
tion within the microbiota can be modified with very
few changes in food consumption. The expansion of
the prebiotic definition to substrates that go beyond
the classical prebiotics and the inclusion of bacteria
other than Bifidobacterium and Lactobacillus have
enabled a greater examination of this intriguing rela-
tionship between diet and the microbiota. It is antici-
pated that these substances can soon be harnessed to
promote populations of newly-identified health pro-
moting bacteria in the gut.
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